 Hemispherx Biopharma continues to work with the FDA on rintatolimod approval for CFS treatment.On December 20, 2012, an FDA Advisory Committee voted in favor of rintatolimod's safety for commercial use (vote 8 to 5), but not in favor of its efficacy (4 to 9).The Complete Response Letter asked for more study data prior to rintatolimod approval.